Market Overview

UPDATE: Morgan Stanley Downgrades Teva Pharmaceutical on Earnings Pressure

Share:
Related TEVA
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks
Have You Heard About This Generic EpiPen Maker?
Mylan To Launch Its Own EpiPen Generic Rival At Half Price (Investor's Business Daily)

In a report published Monday, Morgan Stanley analyst David Risinger downgraded Teva Pharmaceutical (NYSE: TEVA) from Equal-Weight to Underweight, and removed the $40.00 price target.

In the report, Morgan Stanley noted, “Earnings face significant pressure in 2014-2017E when Copaxone, Treanda, and Nuvigil go generic. Copaxone margin pressure offsets cost cuts in our base case. Despite discounted valuation, we believe other stocks in our coverage universe offer a better risk-reward on revenue and growth prospects. Bull/bear cases continue to hinge on Copaxone franchise durability. Brand pipeline success, cost cutting, and external deals could drive upside.”

Teva Pharmaceutical closed on Friday at $38.91.

Latest Ratings for TEVA

DateFirmActionFromTo
Aug 2016BTIG ResearchMaintainsBuy
Jul 2016HSBCUpgradesHoldBuy
Jul 2016OppenheimerMaintainsOutperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!